DENVER--(BUSINESS WIRE)--Ceragenix Pharmaceuticals, Inc. (OTCBB:CGXP), a biopharmaceutical company focused on infectious disease and dermatology, today reported it has enrolled the 90th patient for a clinical study that compares the efficacy of the company’s EpiCeram™ to Cutivate® (a mid strength topical steroid) in patients with moderate to severe atopic dermatitis (eczema).
